Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) Shares Sold by Towerview LLC

Towerview LLC lessened its position in shares of Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS - Free Report) by 70.6% in the 3rd quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 117,500 shares of the company's stock after selling 282,500 shares during the period. Corvus Pharmaceuticals comprises 0.4% of Towerview LLC's investment portfolio, making the stock its 17th biggest holding. Towerview LLC owned about 0.19% of Corvus Pharmaceuticals worth $620,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in CRVS. Vanguard Group Inc. increased its stake in Corvus Pharmaceuticals by 10.6% in the first quarter. Vanguard Group Inc. now owns 1,493,357 shares of the company's stock valued at $2,658,000 after purchasing an additional 142,724 shares during the last quarter. Samlyn Capital LLC boosted its holdings in shares of Corvus Pharmaceuticals by 160.7% in the 2nd quarter. Samlyn Capital LLC now owns 6,123,021 shares of the company's stock valued at $11,144,000 after buying an additional 3,774,658 shares in the last quarter. Marshall Wace LLP purchased a new position in shares of Corvus Pharmaceuticals in the 2nd quarter valued at $136,000. Cubist Systematic Strategies LLC purchased a new stake in Corvus Pharmaceuticals in the second quarter valued at $44,000. Finally, Point72 Asset Management L.P. acquired a new position in Corvus Pharmaceuticals in the second quarter valued at $10,855,000. Institutional investors and hedge funds own 46.64% of the company's stock.

Corvus Pharmaceuticals Trading Down 3.9 %

Shares of CRVS traded down $0.35 during mid-day trading on Thursday, hitting $8.52. The company's stock had a trading volume of 1,218,243 shares, compared to its average volume of 362,133. The firm has a 50-day simple moving average of $6.66 and a 200 day simple moving average of $3.97. Corvus Pharmaceuticals, Inc. has a 1-year low of $1.30 and a 1-year high of $10.00. The firm has a market capitalization of $532.93 million, a P/E ratio of -9.12 and a beta of 1.05.

Analyst Upgrades and Downgrades

A number of research analysts recently issued reports on the company. LADENBURG THALM/SH SH raised their price target on Corvus Pharmaceuticals from $12.00 to $21.00 and gave the stock a "buy" rating in a research note on Monday, September 16th. Mizuho raised shares of Corvus Pharmaceuticals from a "hold" rating to a "strong-buy" rating in a research report on Tuesday, October 22nd. StockNews.com lowered shares of Corvus Pharmaceuticals from a "hold" rating to a "sell" rating in a research note on Thursday, October 31st. Finally, Oppenheimer increased their target price on shares of Corvus Pharmaceuticals from $8.00 to $14.00 and gave the stock an "outperform" rating in a research note on Wednesday. One analyst has rated the stock with a sell rating, three have given a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and a consensus price target of $12.83.

About Corvus Pharmaceuticals

Corvus Pharmaceuticals, Inc, a clinical stage biopharmaceutical company, focuses on the development and commercialization of immune modulator product candidates to treat solid cancers, T cell lymphomas, autoimmune, allergic, and infectious diseases. Its lead product candidate is soquelitinib (CPI-818), a selective covalent inhibitor of interleukin 2 inducible T cell kinase (ITK), which is in a multi-center Phase 1/1b clinical trial for the treatment of peripheral T cell lymphoma, solid tumors, and atopic dermatitis.